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Abstract
Background: Recall bias is likely to occur in vaccine effectiveness studies using self-reported
vaccination history. The validity of patient-reported vaccination status for adults is not well defined.
The objective of this study was to evaluate the validity of self-reported pneumococcal vaccination
history among patients hospitalized with community-acquired pneumonia (CAP).
Methods: Prospective ancillary study of a population-based observational study of hospitalized
patients with CAP in the city of Louisville. To be included in the analysis, patients had to (i) be reached
by phone 30-days after discharge from the hospital and (ii) report that they remembered whether
or not they received a pneumococcal vaccine in the past five years. The vaccination history was
classified as 1) Subjective: patient recollection, or 2) Objective: vaccination records from insurance
companies or primary care physicians.
Results: A total of 2,787 patients who recalled their vaccination history were included in the analysis.
Subjective vaccination history was documented to be inaccurate in 1,023 (37%) patients.
Conclusions: Our study indicates that in adult patients, self-reported data regarding pneumococcal
vaccination is likely to be inaccurate in one out of three patients. This level of recall bias may
incorporate a fatal flaw in vaccine effectiveness studies.
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Introduction
Vaccines are one of the most important public health
interventions for the prevention of infectious diseases [1].
Recent vaccines introduced into the US market, such as the
pneumococcal conjugated vaccine and the rotavirus vaccine,
continue to demonstrate a significant public health impact by
reducing hospitalizations and death [2, 3]. For a new vaccine
to be licensed in the US by the Food and Drug Administration
(FDA), a trial needs to prove that the vaccine is able to prevent
the disease for which it was developed. To test the efficacy of
a new vaccine, studies are performed under well-controlled
conditions. These studies are usually double-blind, randomized
control trials (RCT). One of the primary advantages of
vaccine efficacy studies using the RCT methodology is that
randomization controls for confounding bias. On the other
hand, one of the primary disadvantages of the RCT methodology
is the exclusion of many patients at risk of acquiring the disease
of interest. For example, these studies are likely to exclude
patients who are immunocompromised, since these patients
may not produce enough antibodies after vaccination. Once a
vaccine has proven efficacy for a selected group of patients, the
vaccine is further evaluated in a more “real life” study. These
studies, including all patients at risk of the disease of interest,
will produce data regarding vaccine effectiveness.
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From an FDA regulatory point of view, vaccine efficacy will be
tested in a phase III RCT and vaccine effectiveness in a phase IV
post-license study. One of the most common study designs used
to evaluate vaccine effectiveness is a retrospective case-control
“test-negative” study, where the rate of vaccination among a
population of patients with the disease is compared to the rate of
vaccination among a population of patients without the disease
[4].
One important challenge with this approach is that in
clinical practice, vaccine history data are collected primarily
via selfreport and some patients do not have an accurate
recollection of their vaccine history. Inaccurate recollection of
vaccine history will classify patients in the inappropriate study
group, incorporating a systematic error in the study, defined
as recall bias. Some level of recall bias is expected to occur in
most studies when patients are asked to recall their vaccination
history. If the level of recall bias is significant, the results of
the vaccine effectiveness study may be invalid. Adult patients
hospitalized with community-acquired pneumonia (CAP)with
community-acquired pneumonia (CAP) may be asked to recall
their pneumococcal vaccination history in studies evaluating
effectiveness of pneumococcal vaccination for the prevention of
hospitalizations.
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The level of recall bias in adults regarding their vaccination
history has not been evaluated.
We designed this study to define the level of inappropriate
recollection of pneumococcal vaccination in adults hospitalized
with CAP.

Methods
Study Design & Study Patients: This was an ancillary study
performed during a population-based prospective observational
study of all adults hospitalized with CAP in the city of Louisville,
Kentucky. Patients were included in the primary study if they
had signs and symptoms of lower respiratory infection, an
infiltrate on chest x-ray, and a final diagnosis of CAP. Patients
were included in the vaccine recall ancillary study if they were
able to be reached by phone 30-days after discharge from the
hospital. Once patients were contacted, they were asked if they
recalled their pneumococcal vaccination history. Patients with
no recollection of vaccination history were excluded from the
study. All participants provided written, informed consent.
Pneumococcal vaccination record verification: Patients with
recollection of vaccination history were asked if they received
pneumococcal vaccination (polysaccharide or conjugated).
Patients were also asked to provide the name of his/her current
and prior primary care physician and pharmacy where patient
could have received the vaccine, and current and prior health
insurance coverage. These primary care physicians and local
pharmacies were contacted for verification of pneumococcal
vaccine administration.
In the city of Louisville, pneumococcal vaccination is only
provided to individuals with health insurance, since it is
the insurance company that covers the cost of the vaccine.
Vaccination record was verified with the insurance companies
for all patients included in the study.

Human Subjects Protection: Participants in the primary
University of Louisville Pneumonia Study provided their
consent for inclusion in the vaccine recall ancillary study.

Results
From a total of 3,378 patients who were contacted by telephone
30 days after hospital discharge due to an episode of CAP, 591
patients were excluded because they did not recall vaccination
history. A total of 2,787 patients who recalled their vaccination
history were included in the analysis.
Subjective vaccination history: Based on the self-reported
vaccination history, 1,998 patients indicated that they received
the pneumococcal vaccine prior to hospitalization, and 789
patients indicated that they did not receive pneumococcal
vaccination prior to hospitalization.
Objective vaccination history: Based on insurance records
or primary care physician records, 1,149 patients received the
pneumococcal vaccination prior to hospitalization, and 1,638
patients did not receive pneumococcal vaccination prior to
hospitalization.
Agreement between the two data collection methods were
as follows: 1,062 patients subjectively recalled obtaining the
vaccine and were verified via objective methods, and 702
patients recalled not having received the vaccine and were
objectively documented to have not received it. In 936 patients
subjectively recalled obtaining the vaccine were documented
to not have received the vaccine via objective methods, and 87
patients recalled not having had the vaccine but were objectively
defined as having received it. As depicted in Figure 1, from the
total of 2,787 patients, accurate recollection was documented in
1,764 patients and inaccurate recollection was documented in
1,023 patients (37%).

All vaccination records were obtained corresponding with the
five years prior to hospitalization due to CAP.
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Study Definitions: The vaccination history was classified as 1)
Subjective: Patient Recollection, obtained from the patient at
the time of the telephone interview or 2) Objective: Vaccination
Record, obtained by contacting the insurance company, patient’s
primary care physician, or local pharmacy. The objective
history was considered the gold standard.
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Data Management & Quality: Data collection, management,
and data quality control were performed by the same research
team involved in the primary study.
Statistical Analysis: Categorical data were described using
frequencies and percentages. Medians with interquartile ranges
(IQRs) were used to describe continuous data. P-values were
calculated to define differences between those with and without
accurate recall of vaccine history using Chi-squared or Fisher’s
exact tests for categorical variables and the Mann-Whitney
U-test for continuous variables. Measures of diagnostic accuracy
were calculated using the objective vaccine history as the gold
standard and the Kappa statistic was calculated to define the
agreement between the two data collection methods.
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Fig. 1 Number of patients with accurate versus inaccurate recollection
of pneumococcal vaccination history (n=2,787)

The diagnostic accuracy of subjective vaccination history
with objective vaccination history is depicted in Table 1. The
characteristics of the patients with accurate versus inaccurate
recollection is depicted in Table 2.
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Table 1 Diagnostic accuracy of self-reported (subjective) pneumococcal
vaccine history when compared to medical and health insurance
records (objective) (n=2,787)
Accuracy measure
Sensitivity
Speci�icity
Positive Predictive Value
Negative Predictive Value
Kappa

Percent (95% Con�idence Interval)
92.4 (90.8 - 93.8)
42.9 (40.5 – 45.3)
53.2 (51.0 – 55.3)
89.0 (61.5 – 65.1)
0.318

Table 2 Characteristics of patients with accurate versus inaccurate
self-reported pneumococcal vaccination history (n=2,787)
Characteristic
Age, Median (IQR)
Race: black, n (%)
Sex: male, n (%)
History of cerebrovascular disease, n (%)
History of diabetes, n (%)
History of liver disease, n (%)
Neoplastic disease, n (%)
History of renal disease, n (%)
History of chronic renal failure, n (%)
Height, Median (IQR)
Weight, Median (IQR)
Temperature (Degrees Celsius), Median (IQR)
Heart rate (Beats/Minute), Median (IQR)
Respiratory rate (Breaths/Minute), Median (IQR)
Systolic blood pressure (mmHg), Median (IQR)
Diastolic blood pressure (mmHg), Median (IQR)
Altered mental status on admission, n (%)
Ventilatory support on day 0, n (%)
Pneumonia Severity Index (PSI), Median (IQR)
PSI Class IV or V, n (%)

Accurate
Responders
(n= 1764)
67.8 (21.3)
303 (17)
806 (46)
139 (10)
459 (32)
79 (5)
180 (12)
392 (27)
79 (5)
168 (18)
79 (32)
37.2 (1.2)
106 (27)
22 (7)
116 (34)
57 (17)
172 (12)
173 (12)
77.5 (111.1)
634 (36)

Inaccurate
Responders
(n= 1023)
70.1 (23.2)
196 (19)
430 (42)
119 (14)
321 (38)
47 (6)
93 (11)
279 (33)
73 (9)
168 (15.1)
79 (33)
37.2 (1)
103 (25)
22 (6)
116 (33)
56 (17)
122 (14)
99 (12)
84.9 (115.3)
412 (40)

P-value
<0.001
0.183
0.063
0.001
0.002
0.924
0.349
0.003
0.004
0.057
0.621
0.203
0.002
0.190
0.514
0.388
0.081
0.894
0.006
0.023

Discussion
In this study of hospitalized adult patients with CAP, we
documented that recall of pneumococcal vaccination history is
inaccurate for 37% of the patients. Our study indicates that in
adult patients, the self-report data regarding vaccination history
is likely to be inaccurate in one out of three patients. Recall
tended to be worse among older, sicker adults. Previous studies
have reported similar discordance between self-reported and
verified vaccination status across a variety of age groups and
vaccines [5].
The results of our study have vaccine research implications. In
research studies of vaccine efficacy, the administration of the
vaccine is one of the study interventions; hence, misclassification
of patients is very unlikely. In vaccine effectiveness studies,
defining the vaccine status can be challenging. When vaccination
status is ascertained from adult patients, the potential for
recall bias is significant, to the point that a fatal flaw may be
incorporated into the study [6].
The results of our study also have clinical implications. The
majority of health care workers obtained vaccination history
during a medical interview with the patient. Our study indicates
that verbal questioning, as a method to obtain vaccination
history for adults, should be considered unreliable. In clinical
practice, this may lead to under-vaccination and lack of
protection, or overvaccination and potential for vaccine hyporesponsiveness. In addition, a health care worker may look at
the patient’s electronic medical record to define vaccination
history. If the information in the medical record was obtained
from a prior patient interrogation, the possibility of inaccurate
information will persist. Nearly 20% of all hospitalized patients
with CAP enrolled in the main population-based study were
excluded from this ancillary study due to inability to recall
vaccination history. This lack of recollection intensifies the

magnitude of using patient self-reported data as a reliable
source for information about their immunization status.
Since pneumococcal vaccine administration in the city Louisville
only occurs in those individuals with medical insurance, we
believe that we were able to accurately capture vaccination
records by identifying the medical coverage that patients had at
the time of vaccine administration. However, it is possible that,
due to a lack of recollection from the patients regarding all the
insurance coverage over the prior 5 years from enrollment to this
study, some information may have been missed in relationship
with vaccine administration.
We evaluated only self-reported history of pneumococcal
vaccination. Our findings of 37% of patients having inaccurate
recollection is likely to be similar to the recollection with other
vaccines. In the US, we have now 13 vaccines recommended
for adults aged 19 years and older [7]. Considering the number
of vaccines under clinical research, it is very likely that the
number of vaccines for adults will continue to expand. The
need for adults to remember an expanded number of vaccines
will make recollection of vaccine history more challenging. If
the patient received all medical care under a single health care
system, the vaccine history may be obtained objectively from the
electronic medical record. However, for the majority of adults,
medical care is fragmented, and objective information regarding
vaccination history may be difficult to obtain. Until a national
vaccination registry is available, it will be important for adults
to have a vaccination card or record where accurate vaccination
history may be readily accessible.
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